🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 11 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 02/11/2018 | 175,36 | 177,25 | 171,11 | 173,29 | -1,08% | 3,50% | 1.338.100 |
| 01/11/2018 | 169,51 | 175,75 | 169,25 | 175,19 | +3,38% | 3,83% | 1.369.000 |
| 31/10/2018 | 172,62 | 174,28 | 169,42 | 169,46 | -1,18% | 2,82% | 1.607.500 |
| 30/10/2018 | 171,67 | 173,46 | 168,46 | 171,49 | +0,68% | 2,91% | 1.441.900 |
| 29/10/2018 | 173,49 | 174,98 | 167,35 | 170,34 | +0,51% | 4,40% | 2.700.800 |
| 26/10/2018 | 162,10 | 171,39 | 160,68 | 169,48 | +2,34% | 6,61% | 2.659.500 |
| 25/10/2018 | 157,00 | 167,00 | 153,00 | 165,61 | +1,55% | 8,92% | 2.800.100 |
| 24/10/2018 | 175,02 | 175,74 | 162,53 | 163,09 | -6,36% | 7,55% | 2.053.400 |
| 23/10/2018 | 175,86 | 177,03 | 170,80 | 174,17 | -1,82% | 3,54% | 1.960.500 |
| 22/10/2018 | 175,53 | 178,61 | 172,70 | 177,40 | +0,97% | 3,37% | 1.513.400 |
| 19/10/2018 | 179,35 | 181,13 | 175,05 | 175,69 | -1,79% | 3,39% | 1.905.500 |
| 18/10/2018 | 184,29 | 184,29 | 173,80 | 178,90 | -3,55% | 5,69% | 2.643.400 |
| 17/10/2018 | 185,26 | 185,84 | 181,72 | 185,48 | +0,02% | 2,22% | 886.900 |
| 16/10/2018 | 178,87 | 185,78 | 178,45 | 185,45 | +4,39% | 4,10% | 1.136.700 |
| 15/10/2018 | 180,80 | 181,00 | 177,59 | 177,65 | -2,02% | 1,89% | 1.064.200 |
| 12/10/2018 | 177,20 | 182,19 | 175,90 | 181,32 | +3,22% | 3,55% | 1.257.500 |
| 11/10/2018 | 175,49 | 177,84 | 171,66 | 175,66 | -0,44% | 3,52% | 2.395.200 |
| 10/10/2018 | 184,92 | 185,61 | 176,22 | 176,43 | -4,97% | 5,08% | 1.565.400 |
| 09/10/2018 | 185,34 | 187,96 | 184,78 | 185,66 | +0,17% | 1,72% | 1.087.300 |
| 08/10/2018 | 186,95 | 187,70 | 183,63 | 185,34 | -1,44% | 2,18% | 852.200 |
| 05/10/2018 | 188,64 | 191,50 | 185,37 | 188,05 | -0,30% | 3,25% | 859.800 |
| 04/10/2018 | 191,58 | 192,62 | 187,10 | 188,62 | -1,87% | 2,88% | 935.500 |
| 03/10/2018 | 192,13 | 193,06 | 191,35 | 192,21 | +0,15% | 0,89% | 1.000.900 |
| 02/10/2018 | 191,84 | 192,62 | 190,79 | 191,93 | +0,19% | 0,95% | 941.200 |
| 01/10/2018 | 193,24 | 194,92 | 191,39 | 191,57 | -0,61% | 1,83% | 1.841.400 |
| 28/09/2018 | 189,74 | 193,78 | 189,44 | 192,74 | +1,58% | 2,29% | 2.148.200 |
| 27/09/2018 | 188,00 | 190,00 | 187,50 | 189,74 | +1,66% | 1,33% | 1.381.100 |
| 26/09/2018 | 182,67 | 189,29 | 182,67 | 186,65 | +2,19% | 3,62% | 1.712.100 |
| 25/09/2018 | 183,48 | 184,16 | 182,28 | 182,65 | +0,26% | 1,02% | 835.800 |
| 24/09/2018 | 179,43 | 182,50 | 179,43 | 182,17 | +1,16% | 1,71% | 706.300 |